Immunogenicity Assessment for siRNA Therapeutics: A Risk-Based Proposal for Event-Driven Testing.
Saved in:
| Title: | Immunogenicity Assessment for siRNA Therapeutics: A Risk-Based Proposal for Event-Driven Testing. |
|---|---|
| Authors: | Zhao A; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. an.zhao@regeneron.com., Bond S; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts, USA., Clausen V; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts, USA., Chen M; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Lai CH; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Zylstra J; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Grimaldi C; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Partridge MA; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. |
| Source: | The AAPS journal [AAPS J] 2026 May 19; Vol. 28 (4). Date of Electronic Publication: 2026 May 19. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1550-7416 |
|---|---|
| DOI: | 10.1208/s12248-026-01260-9 |
